188 related articles for article (PubMed ID: 31767510)
1. Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia.
Emsley R; Asmal L; Rubio JM; Correll CU; Kane JM
Schizophr Res; 2020 Nov; 225():55-62. PubMed ID: 31767510
[TBL] [Abstract][Full Text] [Related]
2. Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study.
Rubio JM; Taipale H; Correll CU; Tanskanen A; Kane JM; Tiihonen J
Psychol Med; 2020 Jun; 50(8):1356-1367. PubMed ID: 31190660
[TBL] [Abstract][Full Text] [Related]
3. Cannabis use and clinical outcome in people with first-episode schizophrenia spectrum disorders over 24 months of treatment.
Scheffler F; Phahladira L; Luckhoff H; du Plessis S; Asmal L; Kilian S; Forti MD; Murray R; Emsley R
Psychiatry Res; 2021 Aug; 302():114022. PubMed ID: 34052461
[TBL] [Abstract][Full Text] [Related]
4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
5. Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosis.
Gjerde PB; Dieset I; Simonsen C; Hoseth EZ; Iversen T; Lagerberg TV; Lyngstad SH; Mørch RH; Skrede S; Andreassen OA; Melle I; Steen VM
Schizophr Res; 2018 Jul; 197():253-260. PubMed ID: 29129510
[TBL] [Abstract][Full Text] [Related]
6. Rate and predictors of non-response to first-line antipsychotic treatment in first-episode schizophrenia.
Chiliza B; Asmal L; Kilian S; Phahladira L; Emsley R
Hum Psychopharmacol; 2015 May; 30(3):173-82. PubMed ID: 25758549
[TBL] [Abstract][Full Text] [Related]
7. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
8. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
[No Abstract] [Full Text] [Related]
9. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
[TBL] [Abstract][Full Text] [Related]
10. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
Subotnik KL; Casaus LR; Ventura J; Luo JS; Hellemann GS; Gretchen-Doorly D; Marder S; Nuechterlein KH
JAMA Psychiatry; 2015 Aug; 72(8):822-9. PubMed ID: 26107752
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
[TBL] [Abstract][Full Text] [Related]
12. Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.
Pelayo-Terán JM; Diaz FJ; Pérez-Iglesias R; Suárez-Pinilla P; Tabarés-Seisdedos R; de León J; Crespo-Facorro B
Psychol Med; 2014 Jan; 44(1):37-50. PubMed ID: 23461899
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial.
Hui CLM; Honer WG; Lee EHM; Chang WC; Chan SKW; Chen ESM; Pang EPF; Lui SSY; Chung DWS; Yeung WS; Ng RMK; Lo WTL; Jones PB; Sham P; Chen EYH
Lancet Psychiatry; 2018 May; 5(5):432-442. PubMed ID: 29551618
[TBL] [Abstract][Full Text] [Related]
14. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
15. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
[TBL] [Abstract][Full Text] [Related]
16. A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project.
Bioque M; Llerena A; Cabrera B; Mezquida G; Lobo A; González-Pinto A; Díaz-Caneja CM; Corripio I; Aguilar EJ; Bulbena A; Castro-Fornieles J; Vieta E; Lafuente A; Mas S; Parellada M; Saiz-Ruiz J; Cuesta MJ; Bernardo M;
Int J Neuropsychopharmacol; 2016 Apr; 19(4):. PubMed ID: 26506856
[TBL] [Abstract][Full Text] [Related]
17. Three-Year Naturalistic Study On Early Use Of Long-Acting Injectable Antipsychotics In First Episode Psychosis.
Medrano S; Abdel-Baki A; Stip E; Potvin S
Psychopharmacol Bull; 2018 Jun; 48(4):25-61. PubMed ID: 30618474
[TBL] [Abstract][Full Text] [Related]
18. Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: Study protocol.
Weller A; Gleeson J; Alvarez-Jimenez M; McGorry P; Nelson B; Allott K; Bendall S; Bartholomeusz C; Koval P; Harrigan S; O'Donoghue B; Fornito A; Pantelis C; Paul Amminger G; Ratheesh A; Polari A; Wood SJ; van der El K; Ellinghaus C; Gates J; O'Connell J; Mueller M; Wunderink L; Killackey E
Early Interv Psychiatry; 2019 Dec; 13(6):1345-1356. PubMed ID: 30488637
[TBL] [Abstract][Full Text] [Related]
19. You say "schizophrenia" and I say "psychosis": Just tell me when I can come off this medication.
Zipursky RB; Odejayi G; Agid O; Remington G
Schizophr Res; 2020 Nov; 225():39-46. PubMed ID: 32115315
[TBL] [Abstract][Full Text] [Related]
20. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia.
Takeuchi H; Siu C; Remington G; Fervaha G; Zipursky RB; Foussias G; Agid O
Neuropsychopharmacology; 2019 May; 44(6):1036-1042. PubMed ID: 30514883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
